Literature DB >> 9144896

Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients.

H W Herr1.   

Abstract

Superficial bladder tumors (Ta, Tl, Tis) account for 80% of primary bladder cancers. Transurethral resection and intravesical therapy are successful in controlling the majority of these tumors for up to 5 years. However, patients with multiple or recurrent Ta, Tl and Tis bladder cancer have a lifelong risk of developing stage progression and upper tract tumors. One-half are at risk of having cystectomy eventually and one-third are at risk over a 15-20 year period of dying of bladder cancer.

Entities:  

Mesh:

Year:  1997        PMID: 9144896     DOI: 10.1007/bf02201977

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  12 in total

1.  Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organization for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone.

Authors:  K Kurth; U Tunn; R Ay; F H Schröder; M Pavone-Macaluso; F Debruyne; F ten Kate; M de Pauw; R Sylvester
Journal:  J Urol       Date:  1997-08       Impact factor: 7.450

Review 2.  The treated natural history of high risk superficial bladder cancer: 15-year outcome.

Authors:  M S Cookson; H W Herr; Z F Zhang; S Soloway; P C Sogani; W R Fair
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

Review 3.  An overview of intravesical therapy for superficial bladder tumors.

Authors:  H W Herr; V P Laudone; W F Whitmore
Journal:  J Urol       Date:  1987-12       Impact factor: 7.450

4.  Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup.

Authors:  H W Herr; D D Wartinger; W R Fair; H F Oettgen
Journal:  J Urol       Date:  1992-04       Impact factor: 7.450

5.  The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years.

Authors:  S Holmäng; H Hedelin; C Anderström; S L Johansson
Journal:  J Urol       Date:  1995-06       Impact factor: 7.450

6.  Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial.

Authors:  H W Herr; D M Schwalb; Z F Zhang; P C Sogani; W R Fair; W F Whitmore; H F Oettgen
Journal:  J Clin Oncol       Date:  1995-06       Impact factor: 44.544

7.  Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy.

Authors:  R B Nadler; W J Catalona; M A Hudson; T L Ratliff
Journal:  J Urol       Date:  1994-08       Impact factor: 7.450

8.  A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.

Authors:  R A Badalament; H W Herr; G Y Wong; C Gnecco; C M Pinsky; W F Whitmore; W R Fair; H F Oettgen
Journal:  J Clin Oncol       Date:  1987-03       Impact factor: 44.544

Review 9.  Intravesical BCG: current results, natural history and implications for urothelial cancer prevention.

Authors:  H W Herr
Journal:  J Cell Biochem Suppl       Date:  1992

10.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.

Authors:  A S Sarkis; G Dalbagni; C Cordon-Cardo; Z F Zhang; J Sheinfeld; W R Fair; H W Herr; V E Reuter
Journal:  J Natl Cancer Inst       Date:  1993-01-06       Impact factor: 13.506

View more
  19 in total

1.  Early detection of urothelial premalignant lesions using hexaminolevulinate fluorescence cystoscopy in high risk patients.

Authors:  Salvatore Blanco; Marco Raber; Biagio Eugenio Leone; Luca Nespoli; Marco Grasso
Journal:  J Transl Med       Date:  2010-11-22       Impact factor: 5.531

2.  Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells.

Authors:  Edmund Chiong; I-Ling Lee; Ali Dadbin; Anita L Sabichi; Loleta Harris; Diana Urbauer; David J McConkey; Rian J Dickstein; Tiewei Cheng; H Barton Grossman
Journal:  Clin Cancer Res       Date:  2011-03-17       Impact factor: 12.531

3.  In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors.

Authors:  Enis Coskuner; Ibrahim Cevik; Alp Ozkan; Ozdal Dillioglugil; Atıf Akdas
Journal:  Int Urol Nephrol       Date:  2012-02-28       Impact factor: 2.370

4.  Evaluation of urovysion and cytology for bladder cancer detection: a study of 1835 paired urine samples with clinical and histologic correlation.

Authors:  Haythem Dimashkieh; Daynna J Wolff; T Michael Smith; Patricia M Houser; Paul J Nietert; Jack Yang
Journal:  Cancer Cytopathol       Date:  2013-06-25       Impact factor: 5.284

5.  Prospective evaluation of fluorescence in situ hybridization for diagnosing urothelial carcinoma.

Authors:  Tianhai Lin; Zhenhua Liu; Liangren Liu; Lu Yang; Ping Han; Peng Zhang; Qiang Wei
Journal:  Oncol Lett       Date:  2017-03-27       Impact factor: 2.967

6.  High Dickkopf-1 expression is associated with poor prognosis in patients with advanced urothelial carcinoma.

Authors:  Cheng-Huang Shen; Hsiao-Yen Hsieh; Yuan-Hung Wang; Syue-Yi Chen; Chun-Liang Tung; Jiann-DER Wu; Chang-Te Lin; Michael W-Y Chan; Cheng-DA Hsu; Deching Chang
Journal:  Exp Ther Med       Date:  2010-07-21       Impact factor: 2.447

7.  Application of new technology in bladder cancer diagnosis and treatment.

Authors:  Alvin C Goh; Seth P Lerner
Journal:  World J Urol       Date:  2009-02-22       Impact factor: 4.226

8.  Treatment of nonmuscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors.

Authors:  Ralph Madeb; Dragan Golijanin; Katia Noyes; Susan Fisher; Judith J Stephenson; Stacey R Long; Joy Knopf; Gary H Lyman; Edward M Messing
Journal:  Cancer       Date:  2009-06-15       Impact factor: 6.860

Review 9.  Survivin: a promising biomarker for detection and prognosis of bladder cancer.

Authors:  Vitaly Margulis; Yair Lotan; Shahrokh F Shariat
Journal:  World J Urol       Date:  2007-10-26       Impact factor: 4.226

10.  Chromosomal imbalance in the progression of high-risk non-muscle invasive bladder cancer.

Authors:  Karsten Zieger; Carsten Wiuf; Klaus Møller-Ernst Jensen; Torben Falck Ørntoft; Lars Dyrskjøt
Journal:  BMC Cancer       Date:  2009-05-16       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.